Abstract
Effect of raloxifene on invasive breast cancer incidence in postmenopausal women stratified by Gail risk assessment: Results of the Continuing Outcomes Relevant to Evista (CORE) trial
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have